CLDN5: From structure and regulation to roles in tumors and other diseases beyond CNS disorders

Claudin-5 (CLDN5) is an essential component of tight junctions (TJs) and is critical for the integrity of the blood-brain barrier (BBB), ensuring homeostasis and protection from damage to the central nervous system (CNS). Currently, many researchers have summarized the role and mechanisms of CLDN5 i...

Full description

Bibliographic Details
Published in:	Pharmacological Research
Main Authors:	Yao Ling, Xinxin Kang, Ying Yi, Shenao Feng, Guanshen Ma, Huinan Qu
Format:	Article
Language:	English
Published:	Elsevier 2024-02-01
Subjects:	Tight junctions CLDN5 Tumor Non-central nervous system disorders
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661824000197

Similar Items

Hsa-miR-31-3p targets CLDN8 to compromise skin barrier integrity in psoriasis
by: Yunhua Tu, et al.
Published: (2025-06-01)

Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family
by: Peipei Gao, et al.
Published: (2021-06-01)

Tight junctional protein family, Claudins in cancer and cancer metastasis
by: Wenxiao Ji, et al.
Published: (2025-07-01)

The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis
by: Adrian Georg Simon, et al.
Published: (2023-08-01)

CLDN6 promotes chemoresistance through GSTP1 in human breast cancer
by: Minlan Yang, et al.
Published: (2017-11-01)

CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation
by: Qiu Jin, et al.
Published: (2024-08-01)

Novel Variant in CLDN16: A Further Step in the Diagnosis of Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis—A Case Report
by: Gopal Narang, et al.
Published: (2021-06-01)

Expression of CLDN1 and EGFR in PTC
by: JunJie Wu, et al.
Published: (2024-10-01)

Exploring claudin proteins: from sequence motifs to their impact on tight junction-mediated signaling pathways
by: Lingling Bao, et al.
Published: (2025-09-01)

Association of CLDN molecules with sleep apnea hypopnea syndrome: new biomarker candidates
by: Dan Liu, et al.
Published: (2024-02-01)

In-Depth Bioinformatic Study of the CLDN16 Gene and Protein: Prediction of Subcellular Localization to Mitochondria
by: Erasmia Rouka, et al.
Published: (2019-07-01)

Comprehensive analysis reveals CLDN9 is a new biomarker in human cancers and immunotherapeutic target for glioblastoma multiforme
by: Yuanyuan Zhu, et al.
Published: (2025-06-01)

Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer
by: Yue Wang, et al.
Published: (2024-08-01)

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
by: Keren Jia, et al.
Published: (2022-07-01)

Macrophages promote EMT of bladder cancer cells through secreting TNF-α to regulate CLDN10/β-catenin pathway
by: HAN Na, et al.
Published: (2023-08-01)

Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors
by: Meiying Luo, et al.
Published: (2025-03-01)

Novel compound heterozygous mutations of CLDN16 in a patient with familial hypomagnesemia with hypercalciuria and nephrocalcinosis
by: Alejandro García‐Castaño, et al.
Published: (2020-11-01)

Expression and clinical significance of CLDN7 and its immune-related cells in breast cancer
by: Xiaojie Fan, et al.
Published: (2024-08-01)

Association study of CLDN14 variations in patients with kidney stones
by: Ullah Ihsan, et al.
Published: (2022-02-01)

The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer
by: Akira Matsuishi, et al.
Published: (2024-08-01)

Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer
by: K. Yamamoto, et al.
Published: (2025-09-01)

CLDN1 silencing suppresses the proliferation and migration of airway smooth muscle cells by modulating MMP14
by: Wei Li, et al.
Published: (2023-12-01)

Blue light exposure collapses the inner blood-retinal barrier by accelerating endothelial CLDN5 degradation through the disturbance of GNAZ and the activation of ADAM17
by: Yen-Ju Chan, et al.
Published: (2023-04-01)

Impaired cerebral microvascular endothelial cells integrity due to elevated dopamine in myasthenic model
by: Yue Hao, et al.
Published: (2024-01-01)

The prognostic role of Claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma: a systematic literature review
by: M. Fassan, et al.
Published: (2025-09-01)

Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview
by: Sabrina Rahman Archie, et al.
Published: (2021-10-01)

A CLDN18.2‐Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer
by: Xueying Wang, et al.
Published: (2025-04-01)

Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options
by: Margaretha A. Skowron, et al.
Published: (2023-03-01)

Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity
by: Xingbin Hu, et al.
Published: (2025-05-01)

CNS Tumors and Neurofibromatosis
by: J Gordon Millichap
Published: (1989-02-01)

IL-4, IL-13, TNF-α and IFN-γ Downregulate CLDN8 Expression Through Activating JAK Signaling Pathway in HaCaT Cells
by: Wang X, et al.
Published: (2025-04-01)

CLDN2 inhibits the metastasis of osteosarcoma cells via down-regulating the afadin/ERK signaling pathway
by: Xiaowei Zhang, et al.
Published: (2018-10-01)

The Src-Family Kinases SRC and BLK Contribute to the CLDN6-Adhesion Signaling
by: Naoki Ichikawa-Tomikawa, et al.
Published: (2023-06-01)

Expression of Claudin-9 (CLDN9) in Breast Cancer, the Clinical Significance in Connection with Its Subcoat Anchorage Proteins ZO-1 and ZO-3 and Impact on Drug Resistance
by: Xinguo Zhuang, et al.
Published: (2023-11-01)

Metastatic Cervicomedullary Lesion in the Postpartum Period: A Case-Based Review of CNS Metastases in Pregnancy and Postpartum Period
by: Sarvesh Goyal, et al.

СURRENT CONCEPTS OF THE ROLE OF ALTERED BLOOD-BRAIN BARRIER RESISTANCE IN THE PATHOGENESIS OF CNS DISORDERS. PART II: FUNCTIONS AND MECHANISMS OF THE BLOOD-BRAIN BARRIER DAMAGE
by: D. V. Blinov
Published: (2016-05-01)

CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma
by: Yu Huang, et al.
Published: (2025-03-01)

Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression
by: Akifumi Onagi, et al.
Published: (2024-12-01)

Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers
by: Jun Wu, et al.
Published: (2024-11-01)

High-Dose Acetaminophen Alters the Integrity of the Blood–Brain Barrier and Leads to Increased CNS Uptake of Codeine in Rats
by: Junzhi Yang, et al.
Published: (2022-04-01)